title: Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients.
abstract: The relationship between epidermal growth factor receptor (EGFR) mutation status and EGFR-tyrosine kinase inhibitors (TKI) efficacy in non-small cell lung cancer (NSCLC) patients has been well established. However, there is no available standard to define the optimal testing method and specimen type required for the detection of EGFR mutations. In this study, we compare results of ADx-amplification refractory mutation system (ARMS) and direct sequencing for the detection of EGFR mutation and prediction of EGFR-TKI efficacy for surgery and biopsy tumor tissues in 158 NSCLC patients. For 71 surgery samples, there were 13 and 17 positive samples detected by direct sequencing and ARMS, respectively. For 87 biopsy samples, direct sequencing and ADx-ARMS found 15 and 32 positive samples, respectively. For surgery samples, sensitivity of direct sequencing and ARMS was 72.2% (13/18) and 94.4% (17/18), respectively. For the biopsy samples, sensitivity of direct sequencing and ARMS was 44.1% (15/34) and 94.1% (32/34), respectively. For the biopsy and surgery samples, the ORRs for EGFR positive and negative patients detected by direct sequencing were 46.1 versus 16.7 and 66.7 versus 1.1%, respectively. For ADx-ARMS, the ORR for EGFR positive patients was significantly higher than for negative patients (55.6 vs. 5.6%). The median progression-free survival time of patients with EGFR wild type detected by direct sequencing (4.2 months) was significantly longer than that of patients with wild type detected by ARMS (1.7 months). ARMS has a higher sensitivity and specificity than direct sequencing for EGFR detection of mutation in both surgical and biopsy samples, and the results from ARMS are more consistent with the efficacy of EGFR-TKIs treatment.
authors.affiliation: No. 2 Department of Chemotherapy, Affiliated Tumor Hospital, Guangxi Medical University, No. 71, Heti Road, Nanning, 530021, Guangxi Zhuang Autonomous Zone, China.
authors.forename: Zhou
authors.initials: Z
authors.lastname: Shaozhang
authors.forename: Zhou
authors.initials: Z
authors.lastname: Ming
authors.forename: Peng
authors.initials: P
authors.lastname: Haiyan
authors.forename: Zeng
authors.initials: Z
authors.lastname: Aiping
authors.forename: Yu
authors.initials: Y
authors.lastname: Qitao
authors.forename: Song
authors.initials: S
authors.lastname: Xiangqun
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D018287:Carcinoma, Large Cell / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D004252:DNA Mutational Analysis / Q000379:methods*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D016133:Polymerase Chain Reaction / Q000379:methods*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012680:Sensitivity and Specificity; D015996:Survival Rate
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: Lung Cancer. 2008 May;60(2):175-82
references.pmid: 18061305
references.citation: Lancet. 2008 Nov 22;372(9652):1809-18
references.pmid: 19027483
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: J Clin Oncol. 2012 Apr 1;30(10):1122-8
references.pmid: 22370314
references.citation: J Thorac Oncol. 2007 May;2(5):430-9
references.pmid: 17473659
references.citation: Semin Roentgenol. 2005 Apr;40(2):90-7
references.pmid: 15898407
references.citation: Cancer. 2001 Nov 15;92(10):2639-47
references.pmid: 11745199
references.citation: J Clin Oncol. 2010 Feb 10;28(5):744-52
references.pmid: 20038723
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2653-9
references.pmid: 19414683
references.citation: Lancet Oncol. 2012 May;13(5):466-75
references.pmid: 22512843
references.citation: Lancet Oncol. 2010 Feb;11(2):121-8
references.pmid: 20022809
references.citation: J Exp Clin Cancer Res. 2010 Oct 06;29:132
references.pmid: 20925915
references.citation: Nat Med. 2008 May;14(5):579-84
references.pmid: 18408729
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4539-44
references.pmid: 17008692
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Clin Oncol (R Coll Radiol). 2007 Sep;19(7):499-506
references.pmid: 17537621
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Cancer Res. 2004 Dec 15;64(24):8919-23
references.pmid: 15604253
references.citation: PLoS One. 2011;6(9):e25191
references.pmid: 21949883
references.citation: Cancer Genet Cytogenet. 2009 Dec;195(2):179-82
references.pmid: 19963121
references.citation: J Clin Oncol. 2011 Aug 20;29(24):3316-21
references.pmid: 21788562